IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4

Xenobiotica

Volumn 40, Issue 5, 2010, Pages 331-343

  Burt, Howard J ^a   Galetin, Aleksandra ^a   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

CYP3A4; Drug drug interactions; Time dependent inhibition

Indexed keywords

ALPRAZOLAM; ATORVASTATIN; AZITHROMYCIN; BUSPIRONE; CLARITHROMYCIN; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; MEVINOLIN; VERAPAMIL; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A INHIBITOR; ENZYME INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG INHIBITION; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; BIOLOGICAL MODEL; DRUG INTERACTION; DRUG SCREENING; IC50; KINETICS; PROCEDURES; TIME;

AREA UNDER CURVE; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 77950799568     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498251003698555     Document Type: Article

References (42)

1. Atkinson A, Kenny JR, Grime K. (2005). Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 33(11):1637-1647
2. Berry LM, Zhao Z. (2008). An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2(1):51-59
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815-832
4. Brown HS, Ito K, Galetin A, Houston JB. (2005). Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60(5):508-518
5. Egnell AC, Houston B, Boyer S. (2003). In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 305(3):1251-1262
6. Ernest CS 2nd, Hall SD, Jones DR. (2005). Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312(2):583-591
7. Fowler S, Zhang H. (2008). In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J 10(2):410-424
8. Galetin A, Burt H, Gibbons L, Houston JB. (2006). Prediction of timedependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34(1):166-175
9. Galetin A, Gertz M, Houston JB. (2008). Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4(7):909-922
10. Galetin A, Hinton LK, Burt H, Obach RS, Houston JB. (2007). Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8(7):685-693
11. Galetin A, Ito K, Hallifax D, Houston JB. (2005). CYP3A4 substrate selection and substitution in the prediction of potential drug- drug interactions. J Pharmacol Exp Ther 314(1):180-190
12. Gertz M, Davis JD, Harrison A, Houston JB, Galetin A. (2008). Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab 9(8):785-795
13. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A. (2006). A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7(3):315-334
14. Grime KH, Bird J, Ferguson D, Riley RJ. (2009). Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 36(2-3):175-191
15. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, Tonn GR, Van Horn R, Wang RW, Wong YN, Yang TJ, Obach RS. (2009). The conduct of in vitro studies to address time-dependent inhibition of drugmetabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37(7):1355-1370
16. Hallifax D, Houston JB. (2006). Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34(4):724-6; author reply 727.
17. Houston JB, Galetin A. (2008). Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9(9):940-951.
18. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48(6):662-670
19. Huang SM, Temple R, Throckmorton DC, Lesko LJ. (2007). Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81(2):298-304.
20. Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57(4):473-486
21. Ito K, Ogihara K, Kanamitsu S, Itoh T. (2003). Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31(7):945-954
22. Kalgutkar AS, Obach RS, Maurer TS. (2007). Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug- drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8(5):407-447
23. Krippendorff BF, Neuhaus R, Lienau P, Reichel A, Huisinga W. (2009). Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values. J Biomol Screen 14(8):913-923
24. Maurer TS, Tabrizi-Fard MA, Fung HL. (2000). Impact of mechanismbased enzyme inactivation on inhibitor potency: implications for rational drug discovery. J Pharm Sci 89(11):1404-1414
25. Obach RS. (1997). Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25(12):1359-1369
26. Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35(2):246-255 (Pubitemid 46148737)
27. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316(1):336-348
28. Ogilvie BW, Yerino P, Paris B, Parkinson A. (2007). Effects of substrate incubation time on the IC50 shift for mechanism-based inhibition of CYP1A2 and 3A4. Drug Metab Rev 39:222.
29. Paris B, Kazmi F, Buckley D, Ogilvie B, Gipson A, Parkinson A. (2009). Pitfalls in the design of CYP inhibition studies incorporating a dilution step to examine time-dependent inhibition (TDI) or metabolism-dependent inhibition (MDI). Drug Metab Rev 41(Suppl 3):92.
30. Perloff ES, Mason AK, Dehal SS, Blanchard AP, Morgan L, Ho T, Dandeneau A, Crocker RM, Chandler CM, Boily N, Crespi CL, Stresser DM. (2009). Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 39(2):99-112.
31. Polasek TM, Miners JO. (2007). In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 3(3):321-329.
32. Riley RJ, Grime K, Weaver R. (2007). Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3(1):51-66.
33. Rostami-Hodjegan A, Tucker G. (2004). 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discovery Today: Technol 1(4):441-448
34. Sheiner LB, Beal SL. (1981). Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9(4):503-512
35. Silverman RB. (1995). Mechanism-based enzyme inactivators. Meth Enzymol 249:240-283
36. Stringer RA, Strain-Damerell C, Nicklin P, Houston JB. (2009). Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 37(5):1025-1034
37. Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 37(10-11):1225-1256 (Pubitemid 350035532)
38. von Moltke LL, Durol AL, Duan SX, Greenblatt DJ. (2000). Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 56(3):259-261
39. Wang YH, Jones DR, Hall SD. (2004). Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32(2):259-266
40. Yamamoto T, Suzuki A, Kohno Y. (2004). High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 34(1):87-101.
41. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. (2008). Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9(5):384-394
42. Yeo KR, Yeo WW. (2001). Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 51(5):461-470.